These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 14973152

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
    Watters AA, Jones RN, Leeds JA, Denys G, Sader HS, Fritsche TR.
    J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
    [Abstract] [Full Text] [Related]

  • 4. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
    Koeth LM, Jacobs MR, Good CE, Bajaksouzian S, Windau A, Jakielaszek C, Saunders KA.
    Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
    [Abstract] [Full Text] [Related]

  • 5. In vitro activity of quinupristin/dalfopristin against gram-positive bacteria Haemophilus influenzae and Branhamella catarrhalis in Taiwan.
    Wang FD, Lin ML, Liu CY.
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jun; 63(6):433-9. PubMed ID: 10925532
    [Abstract] [Full Text] [Related]

  • 6. Susceptibility patterns for amoxicillin/clavulanate tests mimicking the licensed formulations and pharmacokinetic relationships: do the MIC obtained with 2:1 ratio testing accurately reflect activity against beta-lactamase-producing strains of Haemophilus influenzae and Moraxella catarrhalis?
    Pottumarthy S, Sader HS, Fritsche TR, Jones RN.
    Diagn Microbiol Infect Dis; 2005 Nov; 53(3):225-31. PubMed ID: 16257168
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study.
    Brown SD, Rybak MJ.
    J Antimicrob Chemother; 2004 Aug; 54 Suppl 1():i7-15. PubMed ID: 15265831
    [Abstract] [Full Text] [Related]

  • 9. PROTEKT 1999-2000: a multicentre study of the antimicrobial susceptibility of respiratory tract pathogens in Japan.
    Inoue M, Kohno S, Kaku M, Yamaguchi K, Igari J, Yamanaka K.
    Int J Infect Dis; 2005 Jan; 9(1):27-36. PubMed ID: 15603993
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. In vitro activity of ertapenem against selected respiratory pathogens.
    Marchese A, Gualco L, Schito AM, Debbia EA, Schito GC.
    J Antimicrob Chemother; 2004 Nov; 54(5):944-51. PubMed ID: 15472001
    [Abstract] [Full Text] [Related]

  • 12. [In vitro activity of trovafloxacin in 238 respiratory pathogens].
    Alarcón T, Domingo D, Prieto N, Sánchez S, López-Brea M.
    Rev Esp Quimioter; 1998 Mar; 11(1):47-51. PubMed ID: 9795289
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Antimicrobial activity of the new macrolide flurithromycin against Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, Branhamella catarrhalis and Staphylococcus aureus.
    Nord CE, Lindmark A, Persson I.
    J Chemother; 1989 Jul; 1(4 Suppl):203-4. PubMed ID: 16312369
    [No Abstract] [Full Text] [Related]

  • 15. Comparative analysis of the antibacterial activity of a novel peptide deformylase inhibitor, GSK1322322.
    O'Dwyer K, Hackel M, Hightower S, Hoban D, Bouchillon S, Qin D, Aubart K, Zalacain M, Butler D.
    Antimicrob Agents Chemother; 2013 May; 57(5):2333-42. PubMed ID: 23478958
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Comparative antibacterial activity of cefpodoxime against Haemophilus influenzae, Streptococcus pyogenes, Streptococcus pneumoniae and Moraxella catarrhalis].
    Wallrauch-Schwarz C, Milatovic D, Braveny I.
    Arzneimittelforschung; 1994 May; 44(5):668-70. PubMed ID: 8024645
    [Abstract] [Full Text] [Related]

  • 19. Antimicrobial activity of tigecycline against recent isolates of respiratory pathogens from Asian countries.
    Ko KS, Song JH, Lee MY, Park S, Kwon KT, Heo ST, Ryu SY, Oh WS, Peck KR, Lee NY.
    Diagn Microbiol Infect Dis; 2006 Aug; 55(4):337-41. PubMed ID: 16631337
    [Abstract] [Full Text] [Related]

  • 20. Antimicrobial susceptibility to levofloxacin and other antibacterial agents among common respiratory pathogens-a Brazilian perspective from the GLOBAL Surveillance Initiative 2001-2002.
    Mendes C, Kiffer CR, Blosser-Middleton RS, Jones ME, Karlowsky JA, Barth A, Rossi F, Andrade S, Sader HS, Thornsberry C, Sahm DF, GLOBAL Surveillance Initiative 2001-2002.
    Clin Microbiol Infect; 2004 Jun; 10(6):521-6. PubMed ID: 15191379
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.